---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-22-000037"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:29:23.955564+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Q2 adjusted EPS $0.82 beats prior year; narrows 2022 organic growth guidance to 4.0-5.2%

## Summary
- Q2 revenue $398M, +2% reported (+4.8% organic); GAAP EPS $0.54 vs $0.41; adjusted EPS $0.82 vs $0.79.
- Full-year 2022 guidance tightened: organic growth 4.0-5.2%; reported revenue $1,557M-$1,575M; adjusted EPS $3.21-$3.29.
- Signed agreement to sell non-core traditional wound care business to Gentell for $28.8M; close expected end of August 2022.
- Codman Specialty Surgical revenue $257.9M (+4.3% organic); Tissue Technologies revenue $140.0M (+5.9% organic).
- Q3 2022 guidance: reported revenue $383M-$391M, organic growth 2.6-4.8%, adjusted EPS $0.78-$0.82.

## SEC filing metadata
- accession: 0000917520-22-000037
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752022000037/0000917520-22-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752022000037/iart-20220727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-22-000037
- JSON: https://secwatch.observer/filing/0000917520-22-000037.json
- Plain text: https://secwatch.observer/filing/0000917520-22-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.